← Leaderboards
Allison W. Kurian
University Of Michigan At Ann Arbor
$2,963,883
Attributed
$6,876,563
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,876,563 · 4
By mechanism
U01$3,675,207 · 1
R01$2,925,084 · 2
P01$276,272 · 1
Top collaborators
- Steven J. Katz11 shared
- Lawrence Chin-I An5 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Steven J. Katz$12,985,075
- Kathleen A Cooney$10,810,865
- Reshma Jagsi$6,831,946
- Stephen B Gruber$33,126,242
- Xihong Lin$29,087,949
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsDiagnosisCancer DiagnosisCancer PatientIndividualized PreventionCaliforniaReportingGenetic TestingTest ResultAffectCancer PreventionCost EffectiveEducationPopulation BasedSubgroupPreventionTechnologyCostCommunicationComplexGuidelinesPrecision GeneticsPrecision OncologyCaring
Grant awards (12)
Personalizing genetic test results management and outcomes after diagnosis of cancer: the Georgia-California SEER Genelink Study$654,143
R01 · FY2025 · CA · contact PI
Personalizing genetic test results management and outcomes after diagnosis of cancer: the Georgia-California SEER Genelink Study$708,444
R01 · FY2024 · CA · contact PI
A population-based virtual solution to reduce gaps in genetic risk evaluation and management in families at high risk for hereditary cancer syndromes: The Georgia-California GeneLINK Trial$631,997
U01 · FY2024 · CA
A population-based virtual solution to reduce gaps in genetic risk evaluation and management in families at high risk for hereditary cancer syndromes: The Georgia-California GeneLINK Trial$742,946
U01 · FY2023 · CA
A population-based virtual solution to reduce gaps in genetic risk evaluation and management in families at high risk for hereditary cancer syndromes: The Georgia-California GeneLINK Trial$750,931
U01 · FY2022 · CA
A population-based virtual solution to reduce gaps in genetic risk evaluation and management in families at high risk for hereditary cancer syndromes: The Georgia-California GeneLINK Trial$752,888
U01 · FY2021 · CA
Genetic testing, treatment use, and mortality after diagnosis of breast and ovarian cancer: The Georgia-California GeneLINK Initiative$247,753
R01 · FY2021 · CA · contact PI
A population-based virtual solution to reduce gaps in genetic risk evaluation and management in families at high risk for hereditary cancer syndromes: The Georgia-California GeneLINK Trial$796,445
U01 · FY2020 · CA
Genetic testing, treatment use, and mortality after diagnosis of breast and ovarian cancer: The Georgia-California GeneLINK Initiative$433,498
R01 · FY2020 · CA · contact PI
Genetic testing, treatment use, and mortality after diagnosis of breast and ovarian cancer: The Georgia-California GeneLINK Initiative$400,626
R01 · FY2019 · CA · contact PI
Genetic testing, treatment use, and mortality after diagnosis of breast and ovarian cancer: The Georgia-California GeneLINK Initiative$480,620
R01 · FY2018 · CA · contact PI
Individualization of Systemic Therapy in Patients with Estrogen Receptor-Pos$276,272
P01 · FY2016 · CA · contact PI